Business Wire

THE-OPEN-GROUP

25.4.2022 14:02:17 CEST | Business Wire | Press release

Share
The Open Group Announces Launch of the TOGAF® Standard, 10th Edition

The Open Group, the vendor-neutral technology consortium, today announced the release of the TOGAF® Standard, 10th Edition, marking a major milestone in the development of the world’s most widely-used Enterprise Architecture framework. Developed by The Open Group Architecture Forum, today’s release introduces a refreshed modular structure which will make it easier to apply the TOGAF framework to different kinds of organizations and styles of architecture.

Building on over twenty-five years of development and constant input from the forum’s global community of EA thought leaders, the TOGAF® Standard, 10th Edition expands the material available to architecture practitioners to make adoption of best practices easier. With greatly expanded guidance and “how-to” material, it enables organizations to operate in an efficient and effective way across a broad range of use-cases, including Agile enterprises and Digital Transformation.

The modular structure provides Enterprise Architects with greater guidance, and simpler navigation, for applying the TOGAF framework alongside its comprehensive fundamental knowledge base. By framing the knowledge base and the topic-specific guidance as separate, formal parts of the TOGAF Standard, the new release will also make it possible to release additional material more frequently while maintaining continuity and stability in its fundamental content.

“The Open Group shares a collective vision of Boundaryless Information Flow™, and the release of the TOGAF® Standard, 10th Edition is a powerful expression of that vision”, commented Steve Nunn, CEO and President of The Open Group. “The next decade of technology and business pressures will require organizations to be more agile, resilient, and adaptable than ever, and that will make a clear approach to architecture more important than ever. I am proud of what The Open Group Architecture Forum has produced for this release, which makes the TOGAF framework significantly more usable by even more businesses while maintaining its core values of consistency, openness, and efficiency.”

“The TOGAF Standard, 10th Edition shows you where to find enduring and universal concepts. It highlights where to find stable, proven best practice. It underscores where to look for new emerging ideas. Bringing together universal concepts, best practice guidance, and emerging ideas is how you adapt the TOGAF Standard for your configured Enterprise Architecture practice,” commented Chris Forde, VP Enterprise Architecture of The Open Group.

The TOGAF® Standard, 10th Edition continues to grow the framework’s ability to enable fundamental aspects of business strategy. These enhancements will also benefit vendors in terms of their ability to deliver competitive new features and services to customers in specialized market segments while adhering to open standards which underpin interoperability.

“The fact that the TOGAF Standard is a living body of knowledge is one of its great advantages,” continued Steve Nunn. “We have now arrived at a point where business strategy and digital solutions are inseparable, and organizations of every size, in every sector, face the need to establish Agile ways of working which continually evolve and adapt. The TOGAF® Standard, 10th Edition shows how the TOGAF ecosystem is itself adapting to this reality, growing with businesses to deliver significant value in times of change.”

- ENDS -

About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 870 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye